Lipogenesis inhibitor is a class of drug that works by inhibiting de novo lipogenesis—the generation of fatty acids in the body. These drugs target enzymes involved in lipogenesis, such as citrate/isocitrate carrier (CIC), ATP-citrate lyase (ACLY), acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS). Lipogenesis plays a role in energy intake and expenditure, lipid deposition, insulin sensitivity, cancer, cardiovascular disease, the immune system, and neurogenesis. Potential therapeutic applications for inhibitors include non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease.[1][2]

References

  1. ↑ Batchuluun, Battsetseg; Pinkosky, Stephen L.; Steinberg, Gregory R. (April 2022). "Lipogenesis inhibitors: therapeutic opportunities and challenges". Nature Reviews Drug Discovery. 21 (4): 283–305. doi:10.1038/s41573-021-00367-2. ISSN 1474-1784. PMC 8758994. PMID 35031766.
  2. ↑ Neuschwander-Tetri, Brent A. (2023). "De Novo Lipogenesis Inhibitors". Need-to-Know NAFLD. CRC Press. pp. 110–118. doi:10.1201/9781003386698-15. ISBN 978-1-003-38669-8.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.